Charles River Laboratories International, Inc. (CRL)
Charles River Laboratories International, Inc. (CRL) Presents at Evercore 8th Annual Healthcare Conference Transcript
Charles River Laboratories International, Inc. (CRL) Presents at Evercore 8th Annual Healthcare Conference Transcript
Charles River Laboratories International, Inc. (CRL) Presents at Jefferies London Healthcare Conference 2025 Transcript
Charles River Laboratories International, Inc. ( CRL ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:30 AM EST Company Participants Birgit Girshick - Corporate Executive VP & COO Conference Call Participants David Windley - Jefferies LLC, Research Division Presentation David Windley Jefferies LLC, Research Division All right. Good morning, everybody.
Charles River (CRL) International Revenue Performance Explored
Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Charles River Laboratories International, Inc. (CRL) Q3 2025 Earnings Call Transcript
Charles River Laboratories International, Inc. ( CRL ) Q3 2025 Earnings Call November 5, 2025 9:00 AM EST Company Participants Todd Spencer - Corporate Vice President of Investor Relations James Foster - Chairman, President & CEO Michael Knell - Interim CFO, Corporate Senior VP & Chief Accounting Officer Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division David Windley - Jefferies LLC, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division Justin Bowers - Deutsche Bank AG, Research Division Casey Woodring - JPMorgan Chase & Co, Research Division Michael Ryskin - BofA Securities, Research Division Ann Hynes - Mizuho Securities USA LLC, Research Division Max Smock - William Blair & Company L.L.C.
Charles River: Mixed Q3 As Strategic Review Disappoints
Charles River Laboratories remains a "Hold" as strategic review yields minimal change and a sale is unlikely. CRL faces slow organic growth, shrinking backlog, and ongoing pressure in its core DSA segment, with limited near-term demand recovery. Cost-cutting, selective divestitures, and a new $1 billion buyback authorization offer some support, but growth headwinds persist.
Charles River (CRL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
CRL's Q3 Earnings Top Estimates, Revenues Decline Y/Y, Stock Falls
Charles River beats Q3 profit and revenue forecasts but posts year-over-year declines and narrows its 2025 outlook.
Charles River Laboratories (CRL) Q3 Earnings and Revenues Surpass Estimates
Charles River Laboratories (CRL) came out with quarterly earnings of $2.43 per share, beating the Zacks Consensus Estimate of $2.32 per share. This compares to earnings of $2.59 per share a year ago.
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Charles River Stock Is Placed Ahead of Q3 Earnings
CRL heads into Q3 earnings with steady RMS growth but faces DSA headwinds from tight biotech budgets.
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Medical Service Industry Stocks Poised to Counter Workforce Issues
Here are three resilient medical services stocks, Labcorp, Charles River Laboratories and Teladoc, that are poised to outperform amid staffing shortages and digital healthcare growth.
